Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
äŒæ¥ã³ãŒãQGEN
äŒç€ŸåQiagen NV
äžå Žæ¥Sep 01, 1996
æé«çµå¶è²¬ä»»è
ãCEOãBernard (Thierry)
åŸæ¥å¡æ°5765
蚌åžçš®é¡Ordinary Share
æ±ºç®ææ«Sep 01
æ¬ç€Ÿæåšå°Hulsterweg 82
éœåžVENLO
蚌åžååŒæNASDAQ OMX NASDAQ Basic NYSE
åœNetherlands
éµäŸ¿çªå·5912 PL
é»è©±çªå·31773556600
ãŠã§ããµã€ãhttps://www.qiagen.com/
äŒæ¥ã³ãŒãQGEN
äžå Žæ¥Sep 01, 1996
æé«çµå¶è²¬ä»»è
ãCEOãBernard (Thierry)
éå»5幎éã®é
åœéç·æ¯æé¡ã¯
0.00
ç±³ãã«ã§ããã
QGEN.NB Final Cash Dividend of gross USD 0.35 paid on Jul 14, 2026 going ex on Jul 07, 2026
QGEN.NB Final Cash Dividend of gross USD 0.25 paid on Jul 10, 2025 going ex on Jul 02, 2025